The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis
Open accessAbstract
Mastocytosis is a hematopoietic neoplasm characterized by expansion of KIT D816V-mutated clonal mast cells in various organs and severe or even life-threatening anaphylactic reactions. Recently, hereditary α-tryptasemia (HαT) has been described as a common genetic trait with increased copy numbers of the α-tryptase encoding gene, TPSAB1, and associated with an increased basal serum tryptase level and a risk of mast cell activation. The purpose of our study was to elucidate the clinical relevance of HαT in patients with mastocytosis. TPSAB1 germline copy number variants were assessed by digital polymerase chain reaction in 180 mastocytosis patients, 180 sex-matched control subjects, 720 patients with other myeloid neoplasms, and 61 additional mastocytosis patients of an independent validation cohort. α-Tryptase encoding TPSAB1 copy number gains, compatible with HαT, were identified in 17.2% of mastocytosis patients and 4.4% of the control population (P < .001). Patients with HαT exhibited higher tryptase levels than patients without HαT (median tryptase in HαT+ cases: 49.6 ng/mL vs HαT− cases: 34.5 ng/mL, P = .004) independent of the mast cell burden. Hymenoptera venom hypersensitivity reactions and severe cardiovascular mediator-related symptoms/anaphylaxis were by far more frequently observed in mastocytosis patients with HαT than in those without HαT. Results were confirmed in an independent validation cohort. The high prevalence of HαT in mastocytosis hints at a potential pathogenic role of germline α-tryptase encoding TPSAB1 copy number gains in disease evolution. Together, our data suggest that HαT is a novel emerging robust biomarker in mastocytosis that is useful for determining the individual patient´s risk of developing severe anaphylaxis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There is a consensus that HαT is a risk modifier of severe anaphylaxis [21,48,49,50,51,52,53].”
From Diagnostic Significance of Tryptase for Suspected Mast Cell Disorders (2023) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In patients with systemic mastocytosis (SM), the risk for developing severe or even life-threatening anaphylaxis is high, especially when a concomitant IgE-dependent allergy or the genetic trait Hereditary a -tryptasemia (H a T) is present.”
From Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review (2021) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, an approximately two to three times higher prevalence of H a T has been reported in two large cohorts of SM patients 25,129 ; also, H a T concurrently occurring with MCAS has been reported. 130,131”
From Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review (2021) · cites this paper as [25]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Further, H a T may be associated with an increased severity of anaphylactic reactions and other mediator-induced symptoms in patients with mastocytosis and venom allergy. 25,129”
From Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review (2021) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“in patients with SM, where it can reach up to 12%–20% (17, 19, 22, 23).”
From Defining “Normal” basal serum tryptase levels: a context-dependent approach to improve diagnostics in systemic mastocytosis (2025) · cites this paper as [22]
In the citing paper
“HαT is enriched in patients with SM,42,43 in Hymenoptera-allergic patients with severe anaphylaxis,44,45 and in patients with idiopathic anaphylaxis.42,43,45,46”
From Mast cell activation syndrome: Current understanding and research needs (2024) · cites this paper as [43]
In the citing paper
“Furthermore, MCAS has been reported in patients with hereditary a-tryptasemia (HaT), an autosomal dominant genetic trait caused by an increased copy-number of the atryptase gene TPSAB1, resulting in increased baseline serum tryptase levels.7,8”
From Low Prevalence of Idiopathic Mast Cell Activation Syndrome Among 703 Patients With Suspected Mast Cell Disorders (2024) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Diagnostic criteria and classification of mastocytosis: a consensus proposal
Valent, P., Horny, H., Escribano, L., Longley, B. J., Li, C. Y., Schwartz, L. B., Marone, G., Núñez, R., Akin, C., Sotlar, K., et al. (2001) · Leukemia Research · doi:10.1016/s0145-2126(01)00038-8 · Cited by 1,114
Self-citationNagata, H., Worobec, A. S., Oh, C. K., Chowdhury, B. A., Tannenbaum, S. H., Suzuki, Y., & Metcalfe, D. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.23.10560 · Cited by 871
Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis
Schwartz, L. B., Metcalfe, D. D., Miller, J. S., Earl, H., & Sullivan, T. (1987) · New England Journal of Medicine · doi:10.1056/nejm198706253162603 · Cited by 784
Valent, P., Akin, C., Escribano, L., Födinger, M., Hartmann, K., Brockow, K., Castells, M., Sperr, W. R., Kluin‐Nelemans, H. C., Hamdy, N. A. T., et al. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01807.x · Cited by 750
Self-citationMastocytosis: 2016 updated WHO classification and novel emerging treatment concepts
Valent, P., Akin, C., & Metcalfe, D. D. (2016) · Blood · doi:10.1182/blood-2016-09-731893 · Cited by 698
Self-citationValent, P., Akin, C., Arock, M., Brockow, K., Butterfield, J. H., Carter, M. C., Castells, M., Escribano, L., Hartmann, K., Lieberman, P., et al. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000328760 · Cited by 654
Self-citationLongley, B. J., Tyrrell, L., Lu, S.-Z., Ma, Y., Langley, K., Ding, T.-G., Duffy, T. P., Jacobs, P., Tang, L. H., & Modlin, I. M. (1996) · Nature Genetics · doi:10.1038/ng0396-312 · Cited by 606
Brockow, K., Jofer, C., Behrendt, H., & Ring, J. (2008) · Allergy · doi:10.1111/j.1398-9995.2007.01569.x · Cited by 523
Mast Cells, Mastocytosis, and Related Disorders
Theoharides, T. C., Valent, P., & Akin, C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1409760 · Cited by 518
Self-citation
Cited by
Sorted by citations
Anaphylaxis: A 2023 practice parameter update
Golden, D. B. K., Wang, J., Waserman, S., Akin, C., Campbell, R. L., Ellis, A. K., Greenhawt, M., Lang, D. M., Ledford, D. K., Lieberman, P., et al. (2023) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2023.09.015 · Cited by 392
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal
Valent, P., Akin, C., Hartmann, K., Alvarez-Twose, I., Brockow, K., Hermine, O., Niedoszytko, M., Schwaab, J., Lyons, J. J., Carter, M. C., et al. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000646 · Cited by 317
Self-citationSystemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management
Pardanani, A. D. (2021) · American Journal of Hematology · doi:10.1002/ajh.26118 · Cited by 181
The ingenious mast cell: Contemporary insights into mast cell behavior and function
Dahlin, J. S., Maurer, M., Metcalfe, D. D., Pejler, G., Sagi‐Eisenberg, R., & Nilsson, G. P. (2021) · Allergy · doi:10.1111/all.14881 · Cited by 159
Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines
Risma, K., Edwards, K. M., Hummell, D. S., Little, F. F., Norton, A. E., Stallings, A. P., Wood, R. A., & Milner, J. D. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.04.002 · Cited by 156
Metadata
- Authors
- Greiner, G., Sprinzl, B., Górska, A., Ratzinger, F., Gurbisz, M., Witzeneder, N., Schmetterer, K. G., Gisslinger, B., Uyanik, G., Hadzijusufovic, E., Esterbauer, H., Gleixner, K. V., Krauth, M. T., Pfeilstöcker, M., Keil, F., Gisslinger, H., Nedoszytko, B., Niedoszytko, M., Sperr, W. R., Valent, P., & Hoermann, G.
- Affiliations
- Ludwig Boltzmann Institute for Hematology and Oncology (AT)
- Hanusch Hospital (AT)
- Gdańsk Medical University (PL)
- Ihr Labor, Medical Diagnostic Laboratories, Vienna, Austria;
- Medical University of Vienna (AT)
- Sigmund Freud Privatuniversität Wien (AT)
- University of Veterinary Medicine Vienna (AT)
- Department of Dermatology, Medical University of Gdańsk, Gdańsk, Poland;
- Innsbruck Medical University (AT)
- Corresponding author
- Hoermann, Gregor
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2021-01-14
- Volume
- 137
- Issue
- 2
- Pages
- 238-247
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC7116780
- OpenAlex
- W3048592971
- Cited by
- 189
- References
- 59
- Citations by year
- 2026: 24 · 2025: 31 · 2024: 28 · 2023: 29 · 2022: 33 · 2021: 40
- FWCI
- 9.18
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
- Health Sciences › Medicine › Surgery › Congenital gastrointestinal and neural anomalies
- Keywords
- hereditary alpha-tryptasemia, mastocytosis, TPSAB1, copy number gain, genetic biomarkers, anaphylaxis, KIT D816V mutation, mast cell activation, myeloid neoplasms
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Female, Genetic Markers, Humans, Male, Mastocytosis, Middle Aged, Tryptases, Young Adult, DNA Copy Number Variations
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
